Read More Pharma Industry News Is the gMG treatment race entering a lower-burden dosing phase? Find out how Regeneron’s cemdisiran review could reshape generalized myasthenia gravis treatment, REGN stock sentiment and siRNA competition today! bySoujanya RaviJune 24, 2026